Sensei Biotherapeutics, INC Schedule 13G passive stakes

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed an amendment to their Schedule 13G, reporting 0 shares beneficially owned in Faeth Therapeutics, Inc.

Millennium Management LLC and affiliated entities have reported beneficial ownership of 3.1% of Sensei Biotherapeutics, Inc. common stock as of June 1, 2026.

Millennium Management and affiliated entities have filed a Schedule 13G reporting a 9.6% beneficial ownership stake in Sensei Biotherapeutics, Inc.

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed a Schedule 13G, reporting beneficial ownership of 132,873 shares, representing 9.9% of Sensei Biotherapeutics, Inc. common stock.

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 9.40% in Sensei Biotherapeutics, Inc., as of March 31, 2026.

Trails Edge Capital Partners, LP, along with its affiliates, has disclosed a 9.9% beneficial ownership stake in Sensei Biotherapeutics, Inc. through a Schedule 13G filing.